Janney Montgomery Scott
KRYS icon

Janney Montgomery Scott’s Krystal Biotech KRYS Stock Holding History

Janney Montgomery Scott’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$858K Buy
2,309
+139
+6% +$41.5K ﹤0.01% 2009
2026
Q1 		$561K Sell
2,170
-228
-10% -$60.7K ﹤0.01% 1972
2025
Q4 		$591K Sell
2,398
-182
-7% -$38.3K ﹤0.01% 2088
2025
Q3 		$455K Buy
2,580
+240
+10% +$35.9K ﹤0.01% 2209
2025
Q2 		$322K Sell
2,340
-43,595
-95% -$6.4M ﹤0.01% 2303
2025
Q1 		$8.28M Sell
45,935
-6,657
-13% -$1.12M 0.02% 596
2024
Q4 		$8.24M Buy
52,592
+15,545
+42% +$2.76M 0.02% 604
2024
Q3 		$6.74M Buy
37,047
+5,415
+17% +$1.04M 0.02% 664
2024
Q2 		$5.81M Buy
31,632
+13,789
+77% +$2.32M 0.02% 673
2024
Q1 		$3.17M Buy
+17,843
New +$2.48M 0.01% 939
2023
Q3 		– Sell
-3,320
Closed -$390K – 2686
2023
Q2 		$390K Buy
+3,320
New +$339K ﹤0.01% 2050

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janney Montgomery Scott's KRYS Position: Q2 2026 in Review

Janney Montgomery Scott increased its Krystal Biotech (KRYS) stake by 6.4% in Q2 2026, buying an estimated $41.5K and bringing the position to 2,309 shares worth $858K. The position accounts for ﹤0.01% of the portfolio, ranked #2009.

Janney Montgomery Scott first reported a position in KRYS in Q2 2023 and has held it in 11 quarters since. The position peaked at $8.28M in Q1 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Janney Montgomery Scott held 2,309 shares of Krystal Biotech worth $858K as of Q2 2026.
  • Janney Montgomery Scott bought 139 Krystal Biotech shares in Q2 2026, an estimated $41.5K.
  • Krystal Biotech made up ﹤0.01% of Janney Montgomery Scott's portfolio in Q2 2026, its #2009 holding.
  • Janney Montgomery Scott first reported a position in Krystal Biotech in Q2 2023 and has held it in 11 quarters since.
  • Janney Montgomery Scott's Krystal Biotech position peaked at $8.28M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.